Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Mitchell Bamberger, MD

Attending Physician
Tri-County Urology
Member of the Healthcare Council

Mitchell Bamberger, MD, MBA, FACS, is an Associate Professor of Surgery at the University of Massachusetts Medical School in Worcester and an Attending Physician at TriCounty Urology Associates and Milford Regional Medical Center. Previously, Dr. Bamberger was the Chief of Urology at Saint Vincent Hospital, a 299 bed acute care teaching hospital in Worcester. He has extensive clinical trial investigational experience with the pharmaceutical industry as well being a consultant to a number of medical device manufacturers. Dr. Bamberger is a board member of the Massachusetts Association of Practicing Urologists. He is a reviewer for the journal Urology and has authored over 50 articles, abstracts, and book chapters. (This is me - Update Profile)


Employment History
2007 - 2008 Attending Physician
Urology Associates of Essex North Inc
2004 - present Attending Physician
Tri-County Urology
1999 - 2007 Division Director of Urology
Fallon Medical Management Co., Inc.
1999 - 2007 Chief of Urology
Saint Vincent Hospital, LLC
1999 - present Associate Professor of Surgery
University of Massachusetts Medical School (UMMS)

GLG Study Groups with Mitchell Bamberger, MD(?)

View All Study Groups with Mitchell Bamberger, MD

GLG NewsSM Analyses by Mitchell Bamberger, MD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Robotic Prostatectomy ?Too soon to tell? | 05-29-2008
Analysis of: Mixed Outcomes in Laparoscopy for Prostates | www.nytimes.com
Author: Mitchell Bamberger, MD, Attending Physician, Tri-County Urology

The data gives a mixed review regarding the robotic assisted radical prostatectomy for prostate cancer.  There is a clear advantage in regards to a significantly decreased risk of bleeding, post operative pain, and earlier return to normal activities.  However, the data does not show a clinical...

Novel immunotherapy for prostate cancer | 04-16-2008
Analysis of: Cell Genesys Announces Encouraging Results from Phase 1/2 Trial of GVAX Immunotherapy for Prostate Cancer in Recurrent Disease | www.pipelinereview.com
Author: Mitchell Bamberger, MD, Attending Physician, Tri-County Urology

Novel therapy for advance recurrent prostate cancer that does not rely upon traditional standard hormone therapy. This has the potential for men to continue to be sexually active while receiving treatment for advanced disease.  It also opens the door to other therapeutic interventions.

Wet pajamas must be back in style??? | 12-06-2007
Analysis of: Desmopressin Acetate (marketed as DDAVP Nasal Spray, DDAVP Rhinal Tube, DDAVP, DDVP, Minirin, and Stimate Nasal Spray) | www.fda.gov
Author: Mitchell Bamberger, MD, Attending Physician, Tri-County Urology

The FDA has made the nasal spray formulation of DDAVP be withdrawn due to potential significant side effects of life threatening hyponatremia (low blood sodium) as well as potential seizures. I an unable to identify the data from this announcement as to why this occured. DDAVP nasal spray has been used...

?Role of IMC-A12 for metastatic prostate cancer | 09-03-2007
Analysis of: Phase II Study of IMC-A12 for Advanced Prostate Cancer Commences Patient Enrollment | www.pipelinereview.com
Author: Mitchell Bamberger, MD, Attending Physician, Tri-County Urology

This immunotherapy is based upon Insulin-like growth factor which may be expressed in prostate cancer.  There is not much data on this.  The study is very limited, 30 patients, and must not have received any chemotherapy prior to enrolling.  The sponsor is IM Clone.  I do not know...

GLG InstituteSM Seminars with Mitchell Bamberger, MD(?)

 
Mitchell Bamberger, MD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Mitchell Bamberger, MD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-10-12T01:47:01.177